Large-scale, multi-country real-world evidence (RWE) studies—including in Central Nervous System (CNS) indications—have the potential to deliver critical new insights.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.